Increasing knowledge of HIV and Hepatitis C during substance abuse treatment

Addictive Disorders and their Treatment

Volumn 4, Issue 2, 2005, Pages 71-76

  Evans, Mark ^a   Hokanson, Patricia S ^b,c   Augsburger, Jay ^b   Sayre, Shelly L ^b   Stotts, Angela L ^b   Schmitz, Joy M ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c University of Texas Mental Sciences Institute   (United States)

Author keywords

Counseling; Hepatitis C; HIV; Knowledge

Indexed keywords

COCAINE; DIAMORPHINE; OPIATE;

ADULT; ARTICLE; COCAINE DEPENDENCE; FEMALE; HEPATITIS C; HEROIN DEPENDENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; PATIENT COUNSELING; PRIORITY JOURNAL; RISK REDUCTION; STATISTICAL SIGNIFICANCE; SUBSTANCE ABUSE;

EID: 20444424618     PISSN: 15315754     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.adt.0000137433.89024.64     Document Type: Article

References (33)

1. Centers for Disease Control and Prevention. Updated U.S. Public Health Service guidelines on the management of occupational exposures to HBX HCV, and HIV and recommendations for post-exposure prophylaxis. MMWR Recomm Rep. 2001; 50:1-52.
2. Alter MJ. Hepatitis C virus infection in the United States. J. Hepatol. 1999;31(Suppl 1):88-91.
3. Garfein RS, Vlahov D, Galai N, et al. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health. 1996;86:655-661.
4. Delage G, Infante-Rivard C, Chiavetta JA, et al. Risk factors for acquisition of hepatitis C virus infection in blood donors: results of a case-control study. Gastroenterology. 1999;116:893-899.
5. Hagan H, Des Jarlais DC. HIV and HCV infection among injecting drug users. Mt Sinai J Med. 2000; 67:423-428.
6. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep. 1998;47:1-39.
7. Tortu S, Neaigus A, McMahon J, et al. Hepatitis C among noninjecting drug users: a report. Subst Use Misuse. 2001;36:523-534.
8. Conry-Cantilena C, VanRaden M, Gibble J, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med. 1996;334:1691-1696.
9. Alter MJ. Epidemiology of hepatitis C. Hepatology. 1997;26:62S-65S.
10. Rosenblum A, Nuttbrock L, McQuistion HL, et al. Hepatitis C and substance use in a sample of homeless people in New York City. J Addict Dis. 2001;20:15-25.
11. Bonkovsky HL, Mehta S. Hepatitis C: a review and update. J Am Acad Dermatol. 2001;44:159-182.
12. Stein MD, Maksad J, Clarke J. Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment. Drug Alcohol Depend. 2001;61:211-215.
13. Aitken CK, Kerger M, Crofts N. Peer-delivered hepatitis C testing and counseling: a means of improving the health of injecting drug users. Drug Alcohol Rev. 2002;21:33-37.
14. Dhopesh VP, Taylor KR, Burke WM. Survey of hepatitis B and C in addiction treatment unit. Am J Drug Alcohol Abuse. 2000;26:703-707.
15. Smyth BP, McMahon J, O'Connor JJ, et al. Knowledge regarding hepatitis C among injecting drug users. Drug-Educ Prev Polic. 1999;6:257-264.
16. van Beek I, Dwyer R, Dore GJ, et al. Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: a retrospective cohort study. BMJ. 1998;317:433-437.
17. Hernandez-Aguado I, Ramos-Rincon JM, Avinio MJ, et al. Measures to reduce HIV infection have not been successful to reduce the prevalence of HCV in intravenous drug users. Eur J Epidemiol. 2001;17: 539-544.
18. Gordon FD. Cost-effectiveness of screening patients for hepatitis C. Am J Med. 1999;107:36S-40S.
19. Alter MJ. Prevention of spread of hepatitis C. Hepatology. 2002;36:S93-S98.
20. Edlin BR. Prevention and treatment of hepatitis C in injection drug users. Hepatology. 2002;36S:210-219.
21. Evans M, Stotts AL, Graham S, et al. Hepatitis C knowledge assessment and counseling within the context of substance abuse treatment. Addict Disord Their Treatment. 2004;3:18-26.
22. Centers for Disease Control and Prevention. National Hepatitis C Prevention Strategy. 2001.
23. Elk R, Grabowski J, Rhoades H, et al. A substance-abuse research-treatment clinic: effective procedures and systems. J Subst Abuse Treat. 1993;10:459-471.
24. SPSS Inc. SPSS for Windows. 9.0 ed. Chicago, IL: SPSS Inc.; 1998.
25. Thomas DL. Hepatitis C epidemiology. Curr Top Microbiol Immunol. 2000;242:25-41.
26. Thomas DL. Hepatitis C. Epidemiologic quandaries. Clin Liver Dis. 2001;5:955-968.
27. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA. 2000;284:450-456.
28. Wejstêal R. Sexual transmission of hepatitis C virus. J Hepatol. 1999;31:92-95.
29. Neaigus A, Miller M, Friedman SR, et al. Sexual transmission risk among noninjecting heroin users infected with human immunodeficiency virus or hepatitis C virus. J Infect Dis. 2001;184:359-363.
30. Rooney G, Gilson RJ. Sexual transmission of hepatitis C virus infection. Sex Transm Infect. 1998;74:399-404.
31. Tengan FM, Eluf-Neto J, Cavalheiro NP, et al. Sexual transmission of hepatitis C virus. Rev Inst Med Trop Sao Paulo. 2001;43:133-137.
32. Pradat P, Trâepo C. HCV: epidemiology, modes of transmission and prevention of spread. Baillieres Best Pract Res Clin Gastroenterol. 2000;14:201-210.
33. Giuliani M, Caprilli F, Gentili G, et al. Incidence and determinants of hepatitis C virus infection among individuals at risk of sexually transmitted diseases attending a human immunodeficiency virus type 1 testing program. Sex Transm Dis. 1997;24:533-537.